Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Ali F Altebainawi, Samiah Alsohimi, Rahaf Alqahtani, Saeedah Alfaifi, Aisha Alharbi, Azzah AlKhayrat, Ahmed Hattan, Meshal Albassam, Omar A Almohammed, Atheer Alkeraidees, Dhay A Alonazi, Weam F Alsalman, Ghaliah Aldamegh, Rasha Alshahrani, Ramesh Vishwakarma
The use of tocilizumab for the management of COVID-19 emerged since it modulates inflammatory markers by blocking interleukin 6 receptors. Concerns regarding higher thrombosis risk while using tocilizumab were raised in the literature. The aim of this study is to investigate the association between tocilizumab therapy and the development of thromboembolic events in critically ill COVID-19 patients. A propensity score-matched, multicenter cohort study for critically ill adult patients with COVID-19...
February 6, 2024: Scientific Reports